Galectin Therapeutics (GALT) Assets Average (2011 - 2026)
Galectin Therapeutics (GALT) posted quarterly Assets Average of $17.6 million for Q1 2026, up 30.6% year-over-year from $13.5 million in Q1 2025, and up 8.93% quarter-over-quarter from $16.2 million in Q4 2025.
Galectin Therapeutics (GALT) Assets Average (2011 - 2026) Analysis & Trends
Galectin Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $17.6 million for Q1 2026.
- In Q1 2026, Assets Average rose 30.6% year-over-year to $17.6 million; the TTM figure through Mar 2026 stood at $17.6 million (up 30.6% YoY), while the FY2025 annual figure was $18.5 million, down 18.97% from the prior year.
- Assets Average for Q1 2026 stood at $17.6 million, up from $16.2 million in the prior quarter.
- The five-year high for Assets Average was $37.7 million in Q1 2022, with the low at $12.6 million in Q2 2025.
- The 5-year median for Assets Average is $21.1 million (2023), against an average of $22.1 million.
- The sharpest annual moves came in 2022 and 2025: Assets Average surged 43.71% in 2022, then plunged 53.07% in 2025.
- Galectin Therapeutics' Assets Average stood at $19.6 million in 2022, then increased by 28.48% to $25.2 million in 2023, then fell by 7.74% to $23.2 million in 2024, then plunged by 30.28% to $16.2 million in 2025, then increased by 8.93% to $17.6 million in 2026.
- Business Quant data shows GALT's Assets Average at $17.6 million in Q1 2026, $16.2 million in Q4 2025, and $14.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 17.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.65 Mn |
| Dec 31, 2025 | 16.20 Mn |
| Sep 30, 2025 | 14.23 Mn |
| Jun 30, 2025 | 12.57 Mn |
| Mar 31, 2025 | 13.51 Mn |
| Dec 31, 2024 | 23.23 Mn |
| Sep 30, 2024 | 28.31 Mn |
| Jun 30, 2024 | 26.77 Mn |
| Mar 31, 2024 | 27.05 Mn |
| Dec 31, 2023 | 25.18 Mn |
| Sep 30, 2023 | 21.12 Mn |
| Jun 30, 2023 | 20.15 Mn |
| Mar 31, 2023 | 20.76 Mn |
| Dec 31, 2022 | 19.60 Mn |
| Sep 30, 2022 | 21.90 Mn |
| Jun 30, 2022 | 29.75 Mn |
| Mar 31, 2022 | 37.72 Mn |
| Dec 31, 2021 | 39.93 Mn |
| Sep 30, 2021 | 35.72 Mn |
| Jun 30, 2021 | 28.15 Mn |